Compare BridgeBio Pharma Inc (BBIO) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Ryanair Holdings plc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Ryanair Holdings plc trades at $59.4 (market cap $29.86B). The key difference: Ryanair Holdings plc is the larger of the two by market cap, and Ryanair Holdings plc pays a 1.51% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | RYAAY | |
|---|---|---|
Market Cap | $16.61B | $29.86B |
Sector | Health | Industrials |
52-Week High | $90.17 | $73.82 |
52-Week Low | $47.29 | $53.24 |
Enterprise Value | $18.16B | $26.83B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
RYAAY trades at $60.19, down 0.59% on the day, with a neutral technical signal and bearish moving averages. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026. Fundamentals show strong profitability with a 12.13% net margin and 22.41% ROE, supported by $13.95B revenue in 2025. Analyst sentiment is positive with a 62.5% buy rating, though recent news highlights pressure from lower fares and higher fuel costs.
The outlook for RYAAY is cautiously optimistic, with potential upside from industry consolidation and a strong balance sheet, but near-term risks include volatile fuel prices, competitive pricing pressure, and geopolitical tensions affecting travel demand. The stock's valuation at a P/E of 14.56 appears reasonable if earnings stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
